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a b s t r a c t
Mutations in HCFC1 (MIM300019), have been recently associated with cblX (MIM309541), an X-linked,
recessive disorder characterized by multiple congenital anomalies including craniofacial abnormalities.
HCFC1 is a transcriptional co-regulator that modulates the expression of numerous downstream target
genes including MMACHC, but it is not clear how these HCFC1 targets play a role in the clinical
manifestations of cblX. To begin to elucidate the mechanism by which HCFC1 modulates disease
phenotypes, we have carried out loss of function analyses in the developing zebraﬁsh. Of the two HCFC1
orthologs in zebraﬁsh, hcfc1a and hcfc1b, the loss of hcfc1b speciﬁcally results in defects in craniofacial
development. Subsequent analysis revealed that hcfc1b regulates cranial neural crest cell differentiation
and proliferation within the posterior pharyngeal arches. Further, the hcfc1b-mediated craniofacial
abnormalities were rescued by expression of human MMACHC, a downstream target of HCFC1 that is
aberrantly expressed in cblX. Furthermore, we tested distinct human HCFC1 mutations for their role in
craniofacial development and demonstrated variable effects on MMACHC expression in humans and
craniofacial development in zebraﬁsh. Notably, several individuals with mutations in either HCFC1 or
MMACHC have been reported to have mild to moderate facial dysmorphia. Thus, our data demonstrates
that HCFC1 plays a role in craniofacial development, which is in part mediated through the regulation of
MMACHC expression.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Mutations in HCFC1 recently have been associated with an
X-linked, recessive disorder characterized by defects in cobalamin
metabolism, nervous system development, neurological impairment,
and failure to thrive (Yu et al., 2013). The cellular and biochemical
manifestations associated with this disorder, methylmalonic acidemia
and homocysteinemia cblX type (cblX; MIM309541), overlap those
observed in individuals with methylmalonic acidemia and homocys-
teinemia cblC type (cblC; MIM277400). cblC is caused by mutations in
MMACHC (Lerner-Ellis et al., 2009, 2006; Liu et al., 2010), which codes
for a protein involved in cobalamin metabolism (Hannibal et al., 2009;
Kim et al., 2009, 2008). HCFC1 is a transcriptional co-regulator that
interacts with multiple proteins including transcription factors to
regulate different biological processes, such as cell proliferation,
migration and cell death (Luciano and Wilson, 2003; Machida et al.,
2009; Van den Berg et al., 2010, p. 4; Yu et al., 2010). The MMACHC
promoter contains conserved binding motifs for HCFC1 and its
transcription factor binding partner THAP11 (Dejosez et al., 2010).
Furthermore, cblX patients with mutations in HCFC1 had markedly
reduced levels of MMACHC expression (Yu et al., 2013). These and
other published data have demonstrated that HCFC1 regulates
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MMACHC expression and that the metabolic defects characteristic of
cblX result from aberrant regulation ofMMACHC expression. However,
the molecular mechanisms underlying the phenotypic spectrum
observed in cblX remain to be elucidated.
HCFC1 was originally discovered as a host transcription factor
during latent reactivation of Herpes Simplex Virus (HSV) infection
(Kristie and Sharp, 1993; La Boissière et al., 1999; Lu et al., 1998).
However, HCFC1 is not a traditional transcription factor because it
lacks a DNA binding domain (Dejosez et al., 2010) and requires
interaction with other proteins to regulate the expression of down-
stream effectors. The kelch domain of HCFC1 serves as a docking
site for protein-protein interactions and is highly conserved across
species (Li et al., 2004). Mutations in HCFC1 that lead to cblX cluster
within the kelch domain, thereby potentially disrupting its interac-
tions with protein partners (Yu et al., 2013) and the expression of
critical downstream effector molecules. Based on recent data from
genome wide ChIP-Seq, HCFC1 binds the promoters of over 5000
genes in conjunction with various protein partners (Michaud et al.,
2013). Thus, it is likely that HCFC1 regulates the development of the
organs and tissues affected in cblX patients via its regulation of
multiple genes including MMACHC.
cblC and cblX are highly similar in that both diseases are
characterized by the accumulation of methylmalonic acid and
homocysteine in blood and/or urine. However, because of the
myriad of genes downstream of HCFC1, the role of MMACHC in the
formation and progression of other overlapping clinical manifesta-
tions associated with cblX remains unclear. For example, although
craniofacial abnormalities are not a cardinal feature associated
with cblC or cblX patients, some individuals with mutations in
either HCFC1 orMMACHC have exhibited mild dysmorphic features
(Cerone et al., 1999; D'Alessandro et al., 2010; Yu et al., 2013).
What remains in question is whether the facial dysmorphia
observed in cblX patients is caused by defects in MMACHC expres-
sion or by aberrant expression of some other HCFC1 target gene.
To begin to address this question we performed transient loss of
function analysis in the developing zebraﬁsh. Zebraﬁsh have two
HCFC1 orthologs, hcfc1a and hcfc1b, whose protein products both
share high levels of sequence identity with human HCFC1. We
show that antisense morpholino oligonucleotide knockdown of
hcfc1b, but not hcfc1a, leads to craniofacial defects in the zebraﬁsh
embryo. Further analysis using molecular markers associated
with neural crest cells (NCCs), which give rise to the cartilagin-
ous structures of the face, suggested that hcfc1b regulates the
division and differentiation of NCCs. In order to determine if
MMACHC plays a role in the craniofacial phenotype in morphant
zebraﬁsh, we co-injected human MMACHC mRNA into the hcfc1b
morphants. This rescued the craniofacial defects resulting from
hcfc1b loss of function, which is consistent with the possibility that
hcfc1b regulates craniofacial development by modulating the
expression of the zebraﬁsh ortholog of human MMACHC. Our
results implicate both HCFC1 and MMACHC as key mediators of
craniofacial development.
Materials and methods
Zebraﬁsh maintenance
For all experiments, embryos [TAB (obtained by crossing adult
Tupfel long ﬁn (TL) with adult AB), Tg(prdm1a:EGFP) or Tg(sox10:
mRFP)] were maintained in embryo medium at 28.5 1C. Zebraﬁsh
(Danio rerio) were maintained at the University of Colorado
Anschutz Medical Campus according to the Institutional Animal
Care and Use Committee (IACUC) guidelines (protocol #B-85411
(08)1D).
Cells and culture conditions
All human subject samples used in this study were collected at
McGill University Health Centre, Montreal, Quebec, Canada after
obtaining informed consent in compliance with the Helsinki
Declaration. Primary ﬁbroblasts were cultured at 37 1C/5% CO2 in
Dulbecco's modiﬁed Eagle's Medium (DMEM; Life Technologies,
Grand Island, NY) supplemented with 10% (v/v) fetal bovine serum
(Life Technologies, Grand Island, NY).
MO and mRNA injections
MOs speciﬁc to each paralog were designed by targeting
unique, paralog-speciﬁc sequences. MOs (2 nl) targeting either
hcfc1a (15.28 ng) mRNA splicing (50-ACCATTAAAGAACTTTCT-
TACCTGT-30), hcfc1b (3.8 ng) translation (50-ACCGAAGTGCCTGCCT-
GAAGAAGCCATGT-30), or mmachc (2 ng, 4 ng, 8 ng, or 16 ng) (50-
GCGTTCACTGGAGATCGCCATTTTT-30) (GeneTools, LLC, Philomath,
OR USA) were injected into the single cell of newly fertilized
embryos. Co-injection with a morpholino targeting the tp53 gene
was performed as a control for off target effects. For mRNA rescue,
embryos were co-injected (2 nl) with MO targeting hcfc1b (3.8 ng),
or MO targeting mmachc (8 ng) and either full length HCFC1
(RefSeq NM_005334.2) mRNA (100, 400, or 800 pg/embryo) or
MMACHC (RefSeq NM_015506.2) mRNA (400, 800, 1600, or
2000 ng/embryo). Concentrations for sub-optimal concentrations
are listed in the supplementary material. Injected embryos were
maintained in embryo water at 28.5 1C and harvested according to
dpf or hpf.
In vitro mRNA synthesis, cloning, and production of HCFC1 mutations
Full length HCFC1 cDNA (Fisher Scientiﬁc, Waltham, MA) was
cloned into the pcDNA 6.2 vector using LR recombination (Life
Technologies, Grand Island, NY). Plasmid encoding full length
HCFC1 was linearized with SalI (Fisher Scientiﬁc, Waltham, MA)
and plasmid encoding full length MMACHC:Myc:DDK (Origene,
Rockville, MD) was linearized with PciI (New England Biolabs,
Ipswich, MA) mRNA was synthesized with the T7 Ultra mMessage
mMachine kit (Life technologies, Grand Island, NY) according
manufacturer's instructions. All HCFC1 mutations were induced
using the QuikChange Site Directed mutagenesis kit (Agilent
Technologies, Santa Clara, CA) according to manufacturer's instruc-
tions. All primer pairs can be found in Supplementary Table 6. All
riboprobes were PCR ampliﬁed from 1 day old embryos and cloned
into the pGem T-easy (Promega, Madison, WI) vector. Probe
synthesis was performed as previously described (Thisse and
Thisse, 2008). All primers used for probe synthesis are included
in Supplementary Table 6.
Staining of cartilage and in situ hybridization
Larvae were collected at 4 or 5 dpf and ﬁxed for 1 h in 2%
paraformaldehyde (Boston BioProducts, Ashland, MA) at room
temperature. Larvae were washed in wash buffer [100 mM Tris
pH 7.5 (Boston BioProducts, Ashland, MA), 10 mM MgCl2 (Boston
BioProducts, Ashland, MA)] and incubated overnight at room
temperature in Alcian blue [0.4% Alcian blue (Sigma, St. Louis,
MO), 100 mM Tris pH 7.5 (Boston BioProducts, Ashland, MA),
10 mM MgCl2 (Boston BioProducts, Ashland, MA), 80% ethanol].
Larvae were sequentially rehydrated in 80% ethanol, 50% ethanol,
and 25% ethanol buffered in 100 mM Tris pH 7.5 (Boston BioPro-
ducts, Ashland, MA). Following rehydration, larvae were bleached
in 3% hydrogen peroxide (Sigma, St. Louis, MO) and 0.5% potassium
hydroxide (KOH) (Boston BioProducts, Ashland, MA) for 10 min at
room temperature. Larvae were washed twice in 25% glycerol
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(Sigma, St. Louis, MO)/0.1% KOH (Boston BioProducts, Ashland,
MA) at room temperature for 10 min. Alizarin red stain (0.01%)
(Sigma, St. Louis, MO) in 25% glycerol (Sigma, St. Louis, MO)/and
100 mM Tris pH 7.5 (Boston BioProducts, Ashland, MA) was added
to the larvae for 30 min at room temperature. Larvae were
destained in 50% glycerol (Sigma, St. Louis, MO)/0.1% KOH (Boston
BioProducts, Ashland, MA) for 10 min and stored at 4 1C. All in situ
hybridization was performed as previously described (Thisse and
Thisse, 2008). Statistical analysis was performed using a Fisher's
exact test.
Western blot and immunohistochemistry
Total protein was isolated from embryos (20) staged at 1 dpf.
Embryos were homogenized in cell lysis buffer (Cell Signaling,
Danvers, MA) and protein was quantitated using Precision Red
(Cytoskeleton Inc., Denver, CO) according to manufacturer's
instructions. Western blotting was performed with approximately
50 μg of protein using 1.25 μg of anti-HCFC1 antibody (Sigma, St.
Louis, MO) and developed with SuperSignal West Pico Chemilu-
minescent substrate (Pierce, Rockford, IL). For immunohistochem-
istry, embryos were ﬁxed in 4% paraformaldehyde for 2 h at room
temperature. Embryos were washed in PBS and embedded in 1.5%
agar and 5% sucrose. Embedded blocks were incubated in 30%
sucrose overnight, dried, frozen with dry ice, and sectioned with a
cryostat (20 μM). Sections were rehydrated in 1 PBS, blocked for
1 h at room temperature in 2% goat serum (Life technologies,
Grand Island, NY) and 2 mg/ml BSA (Sigma, St. Louis, MO). Slides
were incubated with primary antibody (anti-phospoSer10 histone
H3, 1:500 (Cell Signaling, Danvers, MA),) overnight, washed in PBS,
and incubated with appropriate AlexaFlour secondary antibody
(Life technologies, Grand Island, NY) at 1:200 for 1 h at room
temperature. Samples were washed, cover slipped with Vecta-
Shield (Vector Laboratories Burlingame, CA), and imaged with
appropriate ﬁlter. Statistical analysis of immunohistochemistry
was performed using a standard T-test.
RNA isolation, PCR analysis, and chromatin immunoprecipitation
For RNA isolation, larvae were lysed in Trizol (Life Technologies,
Grand Island, NY) (200 μl), and processed according to the
manufacturer's recommendations. Total RNA (500 ng) was con-
verted to cDNA and the level of mmachc was determined using
Sybr green based real time PCR. For RNA isolation from ﬁbroblasts
obtained from healthy donors or patients, approximately 1106
cells were lysed in Trizol (Life Technologies, Grand Island, NY) and
processed according to manufacturer's instructions. Total RNA
(1 μg) was converted into cDNAwith Superscript III Reverse Strand
Synthesis system (Life technologies, Grand Island, NY) according to
manufacturer's protocol. Semi-quantitative PCR was performed
with GoTaq mastermix (Promega, Madison, WI). Quantitative real
time PCR (QPCR) was performed as previously described (Yu et al.,
2013) or with Fast Brilliant III Mastermix (Agilent Technologies,
Santa Clara, CA). ChIP assays were performed as previously
described with anti-HCFC1 antibodies (Sigma, St. Louis, MO)
(Quintana et al., 2011). Sequences of primers are listed in
Supplementary Table 6.
Whole embryo metabolic proﬁle
At 5 days post fertilization pooled embryos (50) were homo-
genized in molecular grade water and centrifuged for 5 min at
10,000XG at 4 1C. Total protein concentration was measured using
the Precision Red Assay (Cytoskeleton Inc. Denver, CO). Super-
natant was removed and metabolites were measured by capillary
stable isotope dilution gas chromatography/mass spectrometry as
previously described (Allen et al., 1993a, 1993b; Stabler et al.,
1993). All metabolic concentrations were normalized according to
total protein content. Metabolites were measured in biological
replicates each consisting of 50 pooled embryos per group, except
for homocysteine, methylmalonic acid, and cystathionine, which
were performed in biological triplicate. Statistics was performed
using a student's T-test.
Results
hcfc1b regulates craniofacial development.
In order to carry out functional analysis of HCFC1 in an in vivo
model, we performed transient knockdown of the zebraﬁsh
orthologs, hcfc1a and hcfc1b. We injected antisense morpholino
oligonucleotides (MO) that speciﬁcally interfere with either the
mRNA splicing of hcfc1a or the translation of hcfc1b mRNA into
freshly fertilized zebraﬁsh eggs. Western blot analysis using anti-
HCFC1 antibodies, which are predicted to recognize a kelch
domain cleavage product of both Hcfc1a and Hcfc1b, conﬁrmed
that the simultaneous inhibition of Hcfc1a and Hcfc1b reduced the
amount of total Hcfc1 protein (Fig. 1A). Based upon amino acid
sequence, Hcfc1a and Hcfc1b are predicted to be different sizes,
however HCFC1 is proteolytically cleaved into multiple N-terminal
and C-terminal fragments. The single band detected by our HCFC1
antibody speciﬁcally recognizes a highly conserved epitope within
the kelch domain. This conserved epitope is present in the N-
terminal cleavage products of both Hcfc1a and Hcfc1b. Therefore,
the intensity of the band shown in Fig. 1A represents the expres-
sion levels of both Hcfc1a and Hcfc1b. Zebraﬁsh gene duplication
can in some cases result in paralogs with independent functions.
In order to properly attribute phenotypes to each paralog we
performed independent knockdown of both hcfc1a and hcfc1b
with separate morpholinos (Fig. 1B and Supplementary Fig. 2E).
Reverse transcription coupled with polymerase chain reaction (RT-
PCR) using primers ﬂanking the targeted splice junction of hcfc1a
or hcfc1b conﬁrmed aberrant mRNA splicing at 1 or 2 days post
fertilization (dpf) (Fig. 1B and Supplementary Fig. 2E).
Although we do not have comprehensive phenotypic informa-
tion on all of the 14 individuals diagnosed with cblX, at least 2
(including the index case), have been reported to have mild to
moderate facial dysmorphia (Yu et al., 2013). We phenotyped hcfc1
morphants for defects in craniofacial development to determine if
there is a correlation between aberrant HCFC1 function and
craniofacial dysmorphism observed in cblX. hcfc1a morphants
appeared normal in size and overall development without any
Fig. 1. Knockdown of hcfc1b causes craniofacial abnormalities. (A) Morpholino
(MO) mediated knockdown of hcfc1a and hcfc1b. Western blot with anti-HCFC1
antibodies performed at 24 h post fertilization (hpf) on wildtype (WT) or on
embryos co-injected with morpholinos targeting hcfc1a or hcfc1b. Pan actin is
shown as a loading control. The HCFC1 antibody is predicted to recognize both
Hcfc1a and Hcfc1b and therefore a single band represents expression of both
isoforms. (B) RT-PCR demonstrating the effectiveness of a MO speciﬁcally targeting
hcfc1a mRNA splicing. Injection of the morpholino causes out of frame excision of
exon 2 and results in a premature stop codon (schematic demonstrates normal and
aberrant splicing).
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obvious craniofacial defect. However, at 5 dpf hcfc1b morphants
had an abnormally small lower jaw. To conﬁrm that knockdown of
hcfc1b resulted in craniofacial defects, we stained larvae with
Alcian blue: Alizarin red to visualize developing facial features. At
5 dpf, knockdown of hcfc1b resulted in a shortening of Meckel's
cartilage, inversion of the ceratohyal, and a complete loss of the
ceratobranchial arches (Fig. 2B and B'). Approximately 60% of the
embryos injected with hcfc1b MO presented with a craniofacial
phenotype (Supplementary Table 1). Interestingly, although hcfc1a
and hcfc1b were expressed similarly, both temporally and spatially,
hcfc1a morphants did not exhibit craniofacial abnormalities
(Fig. 2C and C' and Supplementary Table 1).
Human HCFC1 and zebraﬁsh Hcfc1b share a high degree of
sequence identity, but the level of functionality shared between
these orthologs has not been determined. To determine if the
human and zebraﬁsh proteins are functionally equivalent we
performed rescue experiments with in vitro synthesized human
HCFC1 mRNA. Co-injection of hcfc1b MO with HCFC1 mRNA
rescued the hcfc1b-mediated craniofacial phenotype (Fig. 2D and
D' and Supplementary Table 1) showing that the human protein
Fig. 2. Loss of hcfc1b causes defects in craniofacial development. (A–D) Alcian:Alizarin staining was performed to visualize the developing cartilage in non-injected controls
(NI), hcfc1a morphants (hcfc1a MO), hcfc1b morphants (hcfc1b MO), or embryos co-injected with hcfc1b MO and in vitro synthesized human HCFC1 mRNA. Embryos were
stained at 5 days post fertilization and manual dissection of the viscerocranium and neurocraniumwas performed. Neurocranium is depicted in A–D and the viscerocranium
is depicted in A'–D'.
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can substitute for the zebraﬁsh protein. An appropriate rescue
included an appropriately formed Meckel's cartilage, the appro-
priate directionality of the ceratohyal, and the formation of
ceratobranchial arches. Additionally, these data provide strong
evidence that the craniofacial phenotype caused by hcfc1b MO
injection results speciﬁcally from loss of hcfc1b function and not
off-target MO effects. To further establish that craniofacial defects
were the result of loss of hcfc1b and not hcfc1a or other off target
effects, we performed loss of function analysis with an indepen-
dent hcfc1b targeting MO, which interfered with normal mRNA
splicing. Consistent with our previous results, injection of the
hcfc1b splice site targeting morpholino (hcfc1b SMO) resulted in
craniofacial defects (Supplementary Fig. 1B and B'). Taken together
these data demonstrate that the craniofacial defects associated
with the hcfc1b MO are the direct result of loss of hcfc1b
expression and not some other off target effect.
hcfc1b does not regulate the speciﬁcation or migration of NCCs.
Neural crest cells (NCCs) give rise to multiple different tissues
including the cartilaginous structures of the viscerocranium.
Because the loss of Hcfc1b function causes defects in the cartila-
ginous structures of the viscerocranium we hypothesized that
hcfc1b may regulate the speciﬁcation or migration of developing
NCCs. To address this hypothesis, we ﬁrst assessed speciﬁcation of
NCCs using the Tg(sox10:memRFP) transgenic reporter line, which
marks NCCs with membrane-tethered RFP expressed under the
control of sox10 regulatory DNA (Kucenas et al., 2008). sox10 is a
transcription factor expressed in NCCs and has been used as a
molecular marker to visualize NCC location in vivo (Honoré et al.,
2003, p. 10). Expression of sox10 was similar in control and hcfc1b
MO-injected embryos at the 12 somite stage demonstrating that
hcfc1b does not regulate the speciﬁcation of neural crest cells
(Fig. 3 A and B).
hcfc1b regulates the expression of CNCC speciﬁc genes in the posterior
pharyngeal arches.
A subset of NCCs are further fated to become cranial NCCs
(CNCCs) and migrate to the pharyngeal arches before forming the
cartilaginous structures of the viscerocranium. One possible expla-
nation for the craniofacial abnormalities observed in hcfc1b
morphants could be that NCCs fail to migrate into the pharyngeal
arches, which are populated by the cells that give rise to the
cartilaginous structures of the face. To conﬁrm that CNCCs migrate
normally to the pharyngeal arches, we performed static ﬂuores-
cent imaging using the Tg(sox10:memRFP) reporter ﬁsh. sox10
expression in the pharyngeal arches demonstrated that CNCCs
were localized to arches 1–5 (Fig. 3C and D). Our data have
demonstrated that NCC speciﬁcation and migration are normal
in morphant animals raising the possibility that hcfc1b regulates
an alternative cellular process. One possibility is that CNCCs fail to
express dlx2a, a transcription factor needed for CNCC maintenance
(Akimenko et al., 1994; Sperber et al., 2008). To test this possibility,
we analyzed the expression of dlx2a by RNA in situ hybridization.
dlx2a expression was localized to the forebrain and pharyngeal
arch regions in both wildtype and hcfc1b morphants at 1 dpf
consistent with the hypothesis that CNCC speciﬁcation is normal
in morphant embryos (Fig. 3E and F). Morphant embryos are able
to develop cartilage structures consistent with Meckel's cartilage
and the ceratohyal, however, they do not develop ceratobranchial
cartilages (Fig. 2). Based upon these results, we hypothesized that
hcfc1b is essential for posterior arch development and mainte-
nance. prdm1a is an essential mediator of posterior arch develop-
ment, and loss of prdm1a results in a partially inverted ceratohyal
and the loss of ceratobranchial cartilages 4–7 (Birkholz et al., 2009,
p. 1). This phenotype is consistent with the phenotype we observe
after loss of hcfc1b. Therefore, to test our hypothesis, we measured
the expression of prdm1a, in non-injected and morphant animals
using the Tg(prdm1a:EGFP) transgenic line at 1 dpf. Morphant
embryos demonstrated a signiﬁcant decrease in EGFP expression
relative to non-injected controls consistent with the hypothesis
that hcfc1b regulates posterior arch development (Fig. 3G and H).
Taken together, these data suggest that hcfc1b does not play a
signiﬁcant role in the speciﬁcation or migration of NCCs, but
alternatively that there is a reduction in the differentiation of
craniofacial cartilage in the posterior arches, which would result in
a loss of ceratobranchial cartilage.
hcfc1b is essential for the production of chondrocyte progenitors.
Chondrocytes are one of the differentiated derivatives of CNCCs
and undergo endochondral ossiﬁcation to form the skeletal
structures of the viscerocranium. A possible explanation for the
craniofacial abnormalities we observed in morphant animals,
which is consistent with a reduced level of prdm1a expression, is
Fig. 3. NCCs are speciﬁed and migrate correctly in morphant animals. (A and B)
Dorsal view (anterior to posterior from left to right) of Tg(Sox10:mRFP) embryos
injected with an hcfc1b targeting morpholino (hcfc1b-MO) were visualized for RFP
expression at the 12 somite stage. (C and D) Sagittal view of non-injected (NI) or
hcfc1b MO injected Tg(Sox10:mRFP) larvae at 30 h post fertilization (hpf). Arrows
depict the formation of the pharyngeal arches in both wildtype and morphant
animals. (E–H) In situ hybridization (ISH) of dlx2a in non-injected (NI) and hcfc1b
morphants (hcfc1bMO) at 1 day post fertilization (dpf). (I and J) Lateral view of non-
injected Tg(prdm1a:EGFP) (NI) or Tg(prdm1a:EGFP) embryos injected with the
hcfc1b targeting morpholino (hcfc1b MO). The encircled area depicts posterior arch
expression of EGFP in transgenic animals.
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that CNCCs in the posterior arches fail to diffrentiate. To address
this, we performed RNA in situ hybridization at 3 dpf to detect the
expression of col2a1, a major component of type II collagen whose
expression marks differentiated chondrocytes actively producing
collagen mRNA. We observed that hcfc1b morphants lacked col2a1
expression within the ceratobranchial arches (Fig. 4A and A').
These data are consistent with decreased prdm1a expression in the
posterior arches, with the loss of Alcian blue in the ceratobranchial
cartilages, and with previously published results (Lee et al., 2007).
Taken together these data suggest that hcfc1b regulates the
differentiation of chondrocyte progenitors, which subsequently
leads to the observed craniofacial defects.
Expression of col2a1 is tightly regulated at the transcriptional
level during facial development and the expression of speciﬁc
transcription factors is essential for downstream col2a1 expression
and chondrocyte differentiation. Sox9a and Sox10 are important
regulatory transcription factors associated with CNCC differentia-
tion and both have been implicated in the regulation of col2a1
expression. The Sox9a transcription factor has been shown to bind
to the enhancer element of the col2a1 (Lefebvre et al., 1997, p. 9)
and over-expression of sox10 is sufﬁcient to promote col2a1
expression in avian neural crest cells (Suzuki et al., 2006). Hence,
these two genes can serve as markers for appropriate CNCC
differentiation and defects in col2a1 expression could be caused
by defects in the expression of either gene. In order to determine if
defects in col2a1 are downstream of sox9a and sox10, we measured
the expression of each gene either by RNA in situ hybridization or
via injection of the hcfc1b MO into freshly fertilized embryos
carrying the Tg(sox10:memRFP) reporter, respectively. RNA in situ
hybridization demonstrated a loss of sox9a expression in the
ceratobranchial cartilages (Fig. 4B and B'). Furthermore, visualiza-
tion of sox10 via the transgenic memRFP reporter animal demon-
strated that sox10 expression was absent from areas that give rise
to the ceratobranchial cartilages (Fig. 4C and C'). These data are
consistent with the hypothesis that hcfc1b regulates the differ-
entiation of CNCCs and that a loss of col2a1 is due to defects in
both sox9a and sox10 expression, both of which are necessary for
appropriate col2a1 expression.
hcfc1b regulates cell division in the pharyngeal arches.
We have shown that mRNA levels of prdm1a, sox9a, and col2a1
are reduced in morphant animals, all of which mark CNCCs and
their derivatives. However, this reduction is not due to defects in
CNCC migration or speciﬁcation because sox10 expressing cells
appropriately populate the pharyngeal arches. One possible expla-
nation for the reduction in expression of the markers tested is that
cells within the pharyngeal arches fail to divide. To test the
hypothesis that hcfc1b regulates CNCC cell division within the
pharyngeal arches we performed immunohistochemistry to detect
the level of phosphorylated histone H3 at serine 10 (p-H3), a
Fig. 4. Knockdown of hcfc1b results in reduced expression of the molecular
markers associated with chondrocyte differentiation. (A and B) Ventral view of
RNA in situ hybridization (ISH) of col2a1 or sox9a expression in non-injected (NI)
control larvae or hcfc1b morphants (hcfc1b MO) at 3 days post fertilization (dpf).
(C and C') Ventral view of non-injected (NI) control, Tg(sox10:memRFP) larvae, or
transgenic larvae injected with hcfc1b morpholino (hcfc1b MO) at 3 days post
fertilization.
Fig. 5. hcfc1b regulates cell proliferation. (A and B) Z-stacks for whole mount immunohistochemistry with an anti-pH3 antibody in non-injected Tg(sox10:EGFP) larvae or
larvae injected with an hcfc1b targeting morpholino (hcfc1b MO). (C) Quantiﬁcation of the number of pH3/Sox10 positive cells in non-injected controls or hcfc1b morphants
(p¼2.61431E-05, n¼6 ﬁsh per group). Statistical analysis was performed using a standard T-test.
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marker of cells actively in M-phase of the cell cycle, in Tg(sox10:
EGFP) ﬁsh (Fig. 5A and B). Morphant animals had fewer p-H3þ/
Sox10þ expressing cells relative to the non-injected controls
(Fig. 5C) consistent with the hypothesis that hcfc1b regulates cell
division in the pharyngeal arches. Thus, knockdown of hcfc1b
results in decreased NCC cell division.
Hcfc1b regulates craniofacial development by modulating mmachc
expression.
Mutation of HCFC1 has been shown to reduce the expression of
MMACHC (Yu et al., 2013). Additionally, mutation of MMACHC
causes cblC disease (Lerner-Ellis et al., 2006), a multiple congenital
anomaly characterized primarily by defects in cobalamin metabo-
lism. Notably, mild facial dysmorphia has been associated with
early onset cblC [18,19,25–28]. Based upon these observations we
hypothesized that HCFC1 regulates craniofacial development by
modulating the expression of MMACHC. To begin to address this
hypothesis, we ﬁrst used real time PCR to examine if loss of hcfc1b
resulted in reduced mmachc expression. Consistent with our
hypothesis, hcfc1b MO demonstrated signiﬁcantly reduced levels
of mmachc mRNA at 1 dpf to approximately 10% of the normal
levels (Fig. 6). The hcfc1a MO also reduced mmachc mRNA levels,
but only by about 40% of normal (Fig. 6). Simultaneous knockdown
of hcfc1a and hcfc1b reduced mmachc mRNA levels more than the
individual knockdowns (Fig. 6), indicating that both hcfc1a and
hcfc1b promote mmachc expression.
Our data show that loss of Hcfc1b function causes craniofacial
abnormalities and that both Hcfc1a and Hcfc1b promote mmachc
expression, raising the possibility that Mmachc function contri-
butes to craniofacial abnormalities. To test this possibility we
performed transient knockdown of mmachc with a morpholino
designed to inhibit the translation of mmachc mRNA. Knockdown
ofmmachc resulted in craniofacial abnormalities similar in severity
to those observed after loss of hcfc1b (Fig. 7A–C and Supple-
mentary Table 2), consistent with the idea that Hcfc1 function in
craniofacial development is mediated, at least in part, by Mmachc
function. If this is true, then restoring mmachc expression in the
absence of Hcfc1b function should rescue part or all of the defects
that result from hcfc1b deﬁciency. To address this hypothesis, we
injected in vitro synthesized human MMACHC mRNA with or
without hcfc1b MO into single cell stage eggs and visualized the
developing cartilage at 4 dpf using Alcian blue. Human MMACHC
had no adverse effect on craniofacial development of wild-type
control embryos (Figs. 7D and D') but efﬁciently rescued the
craniofacial defects resulting from hcfc1b knockdown (Figs. 7E
and E'). Furthermore, injection of MMACHC effectively rescued the
mmachc-MO phenotype providing strong evidence that the zebra-
ﬁsh and human MMACHC orthologs share some functional equiva-
lence (Figs. 7F and F'). Consistent with our previous results the co-
injection of sub-optimal levels of hcfc1b-MO and mmachc-MO
induced craniofacial defects (Supplementary Fig. 2C and C'). Sub-
optimal concentrations for each morpholino are deﬁned as con-
centrations that do not induce a craniofacial phenotype indepen-
dently. The exact concentrations can be found in Supplementary
Tables 2 and 3. Taken together, these data support the hypothesis
that MMACHC is a functionally relevant target for HCFC1 in cranio-
facial development.
Mutations in either HCFC1 or MMACHC result in the accumula-
tion of toxic metabolites such as homocysteine and methylmalonic
acid, and high levels of both metabolites have been associated with
the risk of developmental defects (Murphy and Fernandez-Ballart,
2011; Nyhan et al., 1989). To investigate if the facial abnormalities
associated with knockdown of hcfc1b could result from the accu-
mulation of toxic metabolites, we measured the level of the major
metabolites associated with cobalamin metabolism in morphant
animals. Morphant animals did not have increased homocysteine or
methylmalonic acid levels relative to wildtype nor did they have
reduced methionine levels, indicating that cobalamin metabolism is
unperturbed in these animals (Supplementary Table 4), The absence
of elevated homocysteine in morphant animals is likely not the
result of compensatory homocysteine metabolism as there was no
indication of elevated cystathionine or cysteine, where high levels of
either metabolite would suggest increased transsulfuration. Simi-
larly, the absence of any signiﬁcant increase in either dimethylgly-
cine, methylglycine (also known as sarcosine), glycine or methionine
indicates that there has not been any increase in the remethylation
of homocysteine mediated by betaine-homocysteine S-methyltrans-
ferase. Therefore, hcfc1b and mmachc might inﬂuence craniofacial
development by mechanisms that operate independently of one
carbon metabolism.
Distinct HCFC1 mutations have variable effects on MMACHC
expression and craniofacial development
Our data so far have demonstrated that HCFC1 regulates
craniofacial development by modulating the expression of
MMACHC. Also, we have previously demonstrated that two different
HCFC1 mutations identiﬁed in individuals with cblX lead to variable
levels of reduction in MMACHC expression (Yu et al., 2013). This led
us to hypothesize that individual HCFC1 mutations have a different
impact on its activity at downstream promoters, including the
MMACHC promoter. Thus, some mutations might lead to a moderate
reduction in MMACHC expression and to different phenotypic
penetrance. To address this possibility, we measured the level of
MMACHC expression by quantitative real time PCR (qPCR) in cell
lines derived from patient ﬁbroblasts. The p.Ala115Val (c.344C4T)
variant resulted in a signiﬁcant reduction in the level of MMACHC,
while the p.Ala73Val (c.218C4T) variant resulted in a more
moderate reduction in MMACHC expression (Fig. 8A). These data
are consistent with the hypothesis that different mutations in
HCFC1 have different effects on the expression of MMACHC.
Furthermore, these data are consistent with our qPCR results
measuring mmachc expression in morphant animals, where mod-
erate changes in mmachc expression do not cause facial
dysmorphia.
HCFC1 binds to the MMACHC promoter region in both humans
and mice (Dejosez et al., 2010; Michaud et al., 2013) and our
results demonstrate the different mutations have a different effect
Fig. 6. Hcfc1b modulates mmachc expression. (A) Real time quantitative PCR
analysis measuring mmachc expression in non-injected embryos (NI), hcfc1a
morphant embryos (hcfc1a MO), hcfc1b morphant embryos (hcfc1b MO), or
combined hcfc1a and hcfc1b morphant embryos (combo-MO). A total of ten
individual embryos were analyzed per group on 2 independent occasions.
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on MMACHC expression. Therefore, it is plausible that some
mutations in HCFC1 completely abrogate binding to the MMACHC
promoter, but others do not and have an impact on the activity of
the protein rather than the speciﬁcity and binding. To test this idea
we performed chromatin immunoprecipitation (ChIP) with anti-
HCFC1 antibodies to determine if HCFC1 binds to the MMACHC
promoter in ﬁbroblast lines. qPCR analysis demonstrated that
HCFC1 was signiﬁcantly enriched at the MMACHC promoter in
ﬁbroblasts derived from normal healthy individuals (Fig. 8B).
Mutation of p.Ala115Val (c.344C4T) abrogates binding comple-
tely, but in contrast, HCFC1 harboring mutations affecting p.
Ala73Val (c.218C4T) remains enriched at the MMACHC promoter,
although the level of enrichment is severely reduced relative to
healthy individuals (Fig. 8B). These data suggest that the different
HCFC1 variants have different binding afﬁnities for the MMACHC
promoter, which may explain the different effects on phenotypes
mediated by modulation of MMACHC expression.
These observations led us to ask if distinct HCFC1 mutations
have variable effects on craniofacial phenotypes. There are 5 dis-
tinct missense mutations associated with cblX. Of the 5, the p.
Ala115Val (c.344C4T) and p.Ala115Thr (c.343G4A) affect the
same amino acid and are the most common (Yu et al., 2013).
Two of the remaining 3, the p.Ala73Val (c.218C4T) and p.
Ala73Thr (c.217G4A) also affect the same amino acid and are
less common. Thus far we have demonstrated a link between p.
Ala115Val (c.344C4T) mutation, severely reduced MMACHC
expression, and the presence of facial dysmorphia. In contrast
the p.Ala73Val (c.218C4T) is associated with only moderate
changes in MMACHC expression and a lack of facial dysmorphia.
Thus, HCFC1 mutations which result in a signiﬁcant reduction in
the expression of MMACHC, appear to be associated with facial
dysmorphia, while those that only moderately affect MMACHC
expression are not. Due to the limited clinical data available on the
remaining individuals with cblX, it was not possible to determine
the potential variability in craniofacial phenotypes associated with
all of the observed HCFC1 mutations.
In order to further test the hypothesis that different HCFC1
mutations may have a different effect on craniofacial phenotype
we again utilized the zebraﬁsh model. We performed loss of
function rescue experiments with 1 of 4 independent mutant
alleles [p.Ala115Val (c.344C4T), p.Ala115Thr (c.343G4A), p.
Ala73Val (c.218C4T) and p.Ala73Thr (c.217G4A)] in the
Fig. 7. Craniofacial defects associated will loss of hcfc1b are mediated through mmachc expression. (A–F) Staining of cartilage with Alcian blue in non-injected (NI), hcfc1b
morphants (hcfc1b MO), mmachc morphants (mmachc MO), human MMACHC mRNA, hcfc1b MO co-injected MMACHC mRNA, or mmachc-MO injected with MMACHC mRNA.
Numbers of animals are listed in Supplementary Tables 2 and 4. Embryos were stained at 4 days post fertilization and manual dissection of the viscerocranium and
neurocranium was performed. Neurocranium is depicted in A–F and the viscerocranium is depicted in A'–F'.
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developing zebraﬁsh. We characterized the morphant phenotypes
with Alcian blue: Alizarin red staining at 5 dpf and observed that
the p.Ala73Val (c.218C4T) and p.Ala73Thr (c.217G4A) were able
to rescue hcfc1b mediated craniofacial defects to the same extent
as wildtype HCFC1. However, the p.Ala115Val (c.344C4T) and p.
Ala115Thr (c.343G4A) did not rescue the craniofacial defects
(Fig. 9 and Supplementary Table 5). Taken together our data
provide evidence that individual mutations within the HCFC1
protein differentially affect HCFC1 function, which results in
different degrees of phenotypic penetrance.
Our results in patient derived human cell lines suggest that
signiﬁcant decreases in MMACHC expression lead to facial dysmor-
phia, while more moderate decreases do not. Furthermore, our
work in zebraﬁsh has demonstrated that knockdown of hcfc1a
results in moderate changes in mmachc expression without any
facial defects, but in contrast loss of hcfc1b results in dramatic
changes in mmachc expression and facial dsymorphia. Based upon
these results we hypothesized that moderate changes in mmachc
expression are not sufﬁcient to cause craniofacial abnormalities. To
test this hypothesis we co-injected sub-optimal levels of the hcfc1b-
MO (those that do not cause a phenotype) with sub-optimal levels
of the hcfc1a-MO. Consistent with our hypothesis, we observed
craniofacial phenotypes similar to those observed with optimal
levels of the hcfc1b-MO alone (Supplementary Fig. 2D and D').
Discussion
Whole exome sequencing (WES) has recently identiﬁed muta-
tions in HCFC1 that result in cblX, a multiple anomaly disorder and
we have previously shown that the biochemical manifestations of
cblX are mediated via the modulation of MMACHC expression by
HCFC1 (Yu et al., 2013). However, the role of HCFC1 in other
phenotypic manifestations of cblX remains to be elucidated.
Because HCFC1 regulates the expression of thousands of genes
(Michaud et al., 2013) it is difﬁcult to tease out the cellular and
molecular mechanisms underlying each individual phenotypic
manifestation. In order to understand the pathogenicity associated
with mutation of HCFC1 at the cellular and molecular level, we
performed loss of function studies in the developing zebraﬁsh.
We observed that knockdown of hcfc1b, one of the two
zebraﬁsh orthologs of HCFC1, resulted in craniofacial abnormalities
in zebraﬁsh embryos. Furthermore, we have shown that these
craniofacial defects are mediated in part by reduction in MMACHC
expression. This novel role for MMACHC in facial development is
supported by the observation of dysmorphic features in patients
with MMACHC mutations (Biancheri et al., 2001; Carrillo-Carrasco
et al., 2012; Cerone et al., 1999; D'Alessandro et al., 2010;
Martinelli et al., 2011). However, we know that not all mutations
in MMACHC or HCFC1 lead to craniofacial abnormalities. The
spectrum of MMACHC mutations is quite large (Lerner-Ellis et al.,
2009), including 42 different mutations identiﬁed in 204 indivi-
duals with cblC (Martinelli et al., 2011). The effect of each of these
mutations on the levels ofMMACHC expression and function is not
known. Thus, it is quite possible that some mutant forms of
MMACHC retain residual activity, resulting in variable degrees of
phenotypic penetrance. The spectrum of HCFC1mutations is not as
large and we have demonstrated that distinct mutations in HCFC1
have variable effects on the level of MMACHC function and hence,
the occurrence of facial dysmorphia. Based upon these observa-
tions, we suggest that craniofacial abnormalities in individuals
with cblC and cblX may be directly correlated to the effect of the
underlying mutation on the level of MMACHC expression and
function.
Furthermore, mutations in HCFC1 that result in increased levels
of HCFC1 mRNA lead to a very different phenotypic spectrum,
characterized mainly by intellectual disability and no reported
craniofacial abnormalities or metabolic defects (Huang et al.,
2012). Thus, it is likely that these mutations do not result in
decreased MMACHC expression and therefore, do not affect its
function. This is further supported by observations by several
groups that mutations affecting different amino acids within the
same gene can lead to different phenotypes. For example, muta-
tions that truncate the C-terminus of KAT6B result in Genitopa-
tellar Syndrome (MIM606170), whereas mutations that lead to
non-sense mediated decay of KAT6B mRNA lead to Say-Barber-
Biesecker-Young-Simpson syndrome (MIM603736) (Campeau
et al., 2012). Recently these phenotypes have been expanded to
include Blepharophimosis–ptosis–epicanthus inversus syndrome
(MIM110100) (Yu et al., 2014). These data can also be expanded to
other genes such as ADAR, where mutations can cause Aicardi–
Goutieres syndrome (MIM615010) (Rice et al., 2012) or Dyschro-
matosis symmetrica hereditaria (MIM127400) (Miyamura et al.,
2003; Müller et al., 2012). Future studies aimed at characterizing
the functional consequence of distinct HCFC1 mutations, likely
using model organisms, will help improve our understanding of its
Fig. 8. Mutations in HCFC1 abrogate binding and reduce the expression ofMMACHC. (A) QPCR demonstrating the relative expression ofMMACHC in ﬁbroblasts obtained from
a normal reference donor (Ref), subject with mutation c.344C4T [Sbj.1 (344)] or subject with mutation c.218C4T, [Sbj.2 (218)]. QPCR was performed with two independent
biological replicates. np¼0.000593 nnp¼0.000456 Statistical analysis was performed using a standard T-test. (B) Chromatin Immunoprecipitation with either control IgG or
anti-HCFC1 antibodies was performed on ﬁbroblasts obtained from a normal reference donor (Ref), a subject with mutation c.344C4T (Sbj. 1344), or a subject with mutation
c.218C4T, (Sbj. 2218). QPCR with primers ﬂanking the presumed HCFC1 binding motif in the MMACHC regulatory region was used to address occupancy at the promoter
region. Assay was performed in two independent biological replicates. Standard T-test was used to determine statistical signiﬁcance. np¼9.8E-7, nnp¼0.0014. Dark line
demonstrates normalization from IgG reference sample.
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Fig. 9. Mutations in HCFC1 differentially affect craniofacial development. (A–F) Staining of cartilage with Alcian blue on non-injected (NI), hcfc1b MO, or hcfc1b MO
co-injected with the indicated mutated version of HCFC1. Numbers of animals affected are presented in Supplementary Table 5. Embryos were stained at 5 days post
fertilization and manual dissection of the viscerocranium and neurocranium was performed. Neurocranium is depicted in A–F and the viscerocranium is depicted in A'–F'.
A.M. Quintana et al. / Developmental Biology 396 (2014) 94–106 103
role in speciﬁc cell types during development and the effect of
different mutations on downstream effectors and subsequently
their phenotypic outcomes.
An important question that remains to be answered is how
might imbalances in MMACHC expression and function lead to
craniofacial abnormalities? Do mutations in MMACHC cause facial
dysmorphia because they result in the perinatal accumulation of
toxic metabolites such as homocysteine? Homocysteine is terato-
genic and can induce neural tube defects in chick embryos
(Rosenquist et al., 1996). However, case controlled studies measur-
ing homocysteine levels during gestation have failed to correlate
high levels of this metabolite with cleft lip with and without
cleft palate (Shaw et al., 2009), suggesting that mutation of
MMACHC might not cause facial deformities via the accumulation
of toxic metabolites. MMACHC is expressed developmentally
and is a putative cobalamin transport protein with enzymatic
capabilities (Hannibal et al., 2009; Pupavac et al., 2011). Therefore
defects in MMACHC expression or function result in cobalamin
deﬁciencies (Liu et al., 2010). The presence of craniofacial defects in
the absence of any apparent changes in homocysteine, methionine
or methylmalonic acid levels in the developing zebraﬁsh and the
fact that those defects can be prevented by forced MMACHC
expression strongly suggest that some aspects of pathogenesis in
cblC and cblX disease are not solely due to impaired cobalamin
metabolism. Our own observations that individuals with cblX have
variable levels of homocysteine and methylmalonic acid in blood
and urine further support this possibility (Yu et al., 2013). In
addition, cblC exhibits a number of unique clinical sequelae that
are not present in other forms of homocystinuria or methylmalonic
acidemia despite having biochemical markers in common with
them (Weisfeld-Adams et al., 2013). Similarly, a previous report
has shown progressive neurological deterioration and head MRI
abnormalities in a patient with cblC disease despite successful
lowering of methylmalonic acid levels by early intervention with
hydroxycobalamin treatment (Enns et al., 1999). Thus, the accumu-
lation of toxic metabolites may not be the cause of at least some of
the observed phenotypes.
Together these data suggest that MMACHC either has a yet to
be identiﬁed secondary function, which is distinct from its role in
cobalamin metabolism or that it mediates the observed craniofa-
cial abnormalities through another pathway. One such pathway
might be the folate pathway because there is interplay between
cobalamin and folate pathways that could result in folate trapping,
impaired DNA synthesis, and impaired methylation (Chanarin
et al., 1985; Varela-Moreiras et al., 2009). Folate trapping occurs
when cobalamin levels are low causing an increased amount of
methyl tetrahydrofolate that cannot be metabolized which mimics
folate deﬁciency. This is signiﬁcant as folate deﬁciency has been
associated with cleft lip/palate and other facial abnormalities
(Hartridge et al., 1999; Johnson and Little, 2008; Schubert et al.,
2002; Wilcox et al., 2007). More speciﬁcally, polymorphisms in
genes within the folate pathway such as MTHFR, have been
associated with risk and susceptibility of facial abnormalities
(Brouns et al., 2008; Chevrier et al., 2007; Mills et al., 2008;
Mostowska et al., 2010). The biochemical data from our zebraﬁsh
experiments indicate that the hcfc1 morpholino model is not
exhibiting impaired cobalamin metabolism, suggesting that the
occurrence of the methylfolate trap is unlikely. However, a future
stable mutant model may reveal more consistent changes in the
folate cobalamin pathway. It would therefore be interesting to
investigate if mutation of hcfc1b exhibits any of the hematological
sequelae, cellular folate, or global DNA hypomethylation that has
previously been proposed as a consequence of the methylfolate
trap. These possibilities have not yet been fully explored and could
provide useful data regarding the role of both folate and cobalamin
metabolism in facial development.
Developmentally, the craniofacial abnormalities observed in
our zebraﬁsh morphants are likely mediated by the regulation of
neural crest cells (NCCs), a multipotent progenitor cell population.
Our results suggest that HCFC1 regulates the proliferative capacity
of cranial NCCs and highlight an essential role for HCFC1 during
craniofacial development. The role of HCFC1 in cell proliferation
has been previously established, especially in embryonic stem cells
(Dejosez et al., 2010; Van den Berg et al., 2010, p. 4) as well as
other cell lines (Mangone et al., 2010; Parker et al., 2012; Tyagi et
al., 2007). Further, HCFC1 interacts with THAP11, a protein that
regulates stem cell self- renewal (Dejosez et al., 2008) and with
OCT4, a protein that is at the center of a protein network that is
essential for pluripotency (Ding et al., 2012; Van den Berg et al.,
2010, p. 4). Together, these results suggest that HCFC1 regulates
stem cell pluripotency through its interaction with its protein
partners. This idea is further supported by the fact that mutations
in HCFC1 cluster within the kelch protein interaction domain,
which likely abrogates binding to THAP11, OCT4, other protein
partners as well as DNA. Future efforts focused on understanding
normal and mutant HCFC1 activity will be necessary in order to
gain a better understanding of how single point mutations in
HCFC1 lead to various biochemical and developmental defects.
In summary, the functional analysis in a model organism of
HCFC1, a gene associated with human disease, provides direct
evidence for its role in early vertebrate development. The observa-
tion of defects in the development of craniofacial structures in
zebraﬁsh, highlight facial dysmorphia, a previously under-
reported phenotype, as a potential outcome of mutations in both
HCFC1 and its downstream target, MMACHC. Further, our data
sheds new light on how distinct mutations in HCFC1 may lead to
variable phenotypes. These results provide a foundation for future
studies to further elucidate the downstream effectors regulated by
HCFC1 and the developmental pathways affected by its mutation.
The elucidation of developmental mechanisms underlying pheno-
typic outcomes associated with HCFC1 mutations has the potential
to provide future therapeutic targets and treatment options to
alleviate some or all of the disease symptoms.
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